What is Genosco?
Genosco operates at the intersection of medicinal chemistry and computational biology, specializing in the discovery of novel small molecule drugs designed to address high-unmet medical needs. By leveraging its proprietary Master Scaffolds, the company has developed a robust portfolio targeting complex pathologies, including oncology, inflammatory conditions, and neurodegenerative disorders such as Parkinson's disease. The organization distinguishes itself through a highly integrated interdisciplinary approach, focusing on the selective inhibition of protein kinases. With a deep expertise in structural drug design and pharmacology, Genosco is currently advancing inhibitors for critical targets such as SYK, EGFRm+, and LRRK2, positioning itself as a formidable player in the precision medicine landscape.
How much funding has Genosco raised?
Genosco has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Genosco
PPP
Public-Private Partnership
What's next for Genosco?
With the recent capital injection, Genosco is well-positioned to accelerate its research and development initiatives, specifically focusing on the transition of its lead kinase inhibitors from the laboratory to clinical trials. The strategic roadmap involves scaling its drug discovery group to enhance the throughput of its Master Scaffolds platform, thereby increasing the probability of identifying breakthrough therapies for patients with limited treatment options. Furthermore, the company is expected to prioritize regulatory engagement and potential licensing partnerships to maximize the commercial impact of its pipeline. By maintaining a rigorous focus on signal pathway modulation, Genosco aims to solidify its market leadership and deliver transformative pharmaceutical solutions that address the most challenging human diseases.
See full Genosco company page
